The Fridley, Minn.-based company said the DBS Therapy system is licensed by Health Canada for treating diseases such as Parkinsons and for treating symptoms such as tremors through the application of mild electrical stimulation to precise targets in the brain.
The SureTune3 provides patient-specific visualization of lead location and simulated volume of neural activation to aid physicians in decision making during the programming of DBS therapy treatments. Advancements in the software include a 3D deformable atlas to allow for precise definition of anatomical structures and improved, streamlined workflow when using the Medtronic StealthStation platform, the company said.
“It is a vital goal to obtain the best clinical outcomes for our patients. Software – such as SureTune3 – can accurately visualize patient-specific stimulation settings and expedite the data while treating patients with DBS. Further, this software can allow our hospital server to integrate all the procedure and patient data so I can provide more personalized case management with faster programming,” Dr. Christopher Honey of the University of British Columbia said in a prepared statement.
“As the pioneer in DBS therapy with more than 30 years of experience, Medtronic is committed to continuing to advance our technology. The latest innovations to our SureTune technology allow for more precise, efficient treatment while also improving patient management with centralized data storage for easy reference. With more than 150,000 patients implanted worldwide, we strive to continue to improve both the physician and patient experience with our solutions,” Medtronic brain therapy division prez Brett Wall said in a press release.
Last September, Medtronic said the FDA granted 510(k) clearance for its StealthStation software, which is designed to help plan the placement of the leads used for deep-brain stimulation therapy.